Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other financing activities: 2020-2024

Historic Other financing activities for Keros Therapeutics (KROS) over the last 5 years, with Dec 2024 value amounting to $171,000.

  • Keros Therapeutics' Other financing activities rose 381.48% to $130,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $324,000, marking a year-over-year decrease of 1.22%. This contributed to the annual value of $171,000 for FY2024, which is 81.91% up from last year.
  • Per Keros Therapeutics' latest filing, its Other financing activities stood at $171,000 for FY2024, which was up 81.91% from $94,000 recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Other financing activities registered a high of $420,000 during FY2020, and its lowest value of $87,000 during FY2022.
  • Moreover, its 3-year median value for Other financing activities was $94,000 (2023), whereas its average is $117,333.
  • Its Other financing activities has fluctuated over the past 5 years, first plummeted by 76.19% in 2021, then surged by 81.91% in 2024.
  • Over the past 5 years, Keros Therapeutics' Other financing activities (Yearly) stood at $420,000 in 2020, then slumped by 76.19% to $100,000 in 2021, then dropped by 13.00% to $87,000 in 2022, then grew by 8.05% to $94,000 in 2023, then skyrocketed by 81.91% to $171,000 in 2024.